These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 12094708)
21. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH]. Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845 [TBL] [Abstract][Full Text] [Related]
22. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766 [TBL] [Abstract][Full Text] [Related]
23. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia]. Shang XJ; Liu ZY; Liu ZF; Sun YH; Huang YF Zhonghua Nan Ke Xue; 2008 Mar; 14(3):227-30. PubMed ID: 18488335 [TBL] [Abstract][Full Text] [Related]
24. Vaporesection for managing benign prostatic hyperplasia using a 2-microm continuous-wave laser: a prospective trial with 1-year follow-up. Fu WJ; Hong BF; Yang Y; Zhang X; Gao JP; Zhang L; Wang XX BJU Int; 2009 Feb; 103(3):352-6. PubMed ID: 18778340 [TBL] [Abstract][Full Text] [Related]
25. [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery]. Granados EA Arch Esp Urol; 1998 Sep; 51(7):675-9. PubMed ID: 9807893 [TBL] [Abstract][Full Text] [Related]
26. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205 [TBL] [Abstract][Full Text] [Related]
27. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice. Chung BH; Hong SJ; Lee MS Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110 [TBL] [Abstract][Full Text] [Related]
28. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia]. Xu J; Qian WQ; Song JD Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754 [TBL] [Abstract][Full Text] [Related]
29. [Quality of life assessment of the male with benign prostate hypertrophy]. Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641 [TBL] [Abstract][Full Text] [Related]
30. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. Fourcade RO; Théret N; Taïeb C; BJU Int; 2008 May; 101(9):1111-8. PubMed ID: 18279447 [TBL] [Abstract][Full Text] [Related]
31. [Effect of transurethral resection of prostate on quality of life in aged patients with benign prostatic hyperplasia]. Cheng NZ; Tang ZY; Liu Y; Liu XS; Qi L Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 33(10):975-8. PubMed ID: 19001744 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Grise P; Plante M; Palmer J; Martinez-Sagarra J; Hernandez C; Schettini M; Gonzalez-Martin M; Castiñeiras J; Ballanger P; Teillac P; Rolo F; Baena V; Erdmann J; Mirone V Eur Urol; 2004 Oct; 46(4):496-501; discussion 501-2. PubMed ID: 15363567 [TBL] [Abstract][Full Text] [Related]
33. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia]. Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379 [TBL] [Abstract][Full Text] [Related]
34. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F; Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011 [TBL] [Abstract][Full Text] [Related]
35. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment. Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175 [TBL] [Abstract][Full Text] [Related]
36. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M; BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317 [TBL] [Abstract][Full Text] [Related]
37. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. Desgrandchamps F; Droupy S; Irani J; Saussine C; Comenducci A BJU Int; 2006 Jul; 98(1):83-8. PubMed ID: 16831149 [TBL] [Abstract][Full Text] [Related]
39. The natural history of benign prostatic hyperplasia. Fitzpatrick JM BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045 [TBL] [Abstract][Full Text] [Related]
40. [A pilot study of photon therapy for benign prostate hyperplasia (a report of 30 cases)]. Mo Z; Huang H; Long D; Yang Z Zhonghua Nan Ke Xue; 2004 Oct; 10(10):764-6, 770. PubMed ID: 15562792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]